CSIMarket Company Name, Ticker, Industry, else..
 
Cadrenal Therapeutics Inc  (NASDAQ: CVKD)
 
Price: $1.1700 $-0.01 -0.847%
Day's High: $1.1888999938964844 Week Perf: -4.1 %
Day's Low: $ 1.11 30 Day Perf: -36.41 %
Volume (M): 84,054 52 Wk High: $ 14.64
Volume (M$): $ 0 52 Wk Avg: $6.84
Open: $1.16 52 Wk Low: $1.11



 Market Capitalization (Millions $) 3
 Shares Outstanding (Millions) 3
 Employees 5
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -13
 Cash Flow (TTM) (Millions $) -8
 Capital Exp. (TTM) (Millions $) 0

Business Description


Cadrenal Therapeutics Inc is a biotechnology company focused on developing innovative therapies for the treatment of kidney diseases. The company aims to address the unmet medical needs in this field by developing novel drugs that can improve patients' outcomes and quality of life. Cadrenal Therapeutics Inc leverages groundbreaking research and cutting-edge technologies to discover and develop new therapeutic approaches. The company's mission is to transform the treatment landscape for kidney diseases and provide hope to patients suffering from these conditions.


   Company Address: 822 A1A North Ponte Vedra 32082 FL
   Company Phone Number: 300-0701   Stock Exchange / Ticker: NASDAQ CVKD


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
BMY   -6.83%    
LLY   -3.53%    
PFE   -4.46%    
REGN   -7.13%    
TGTX   -3.99%    
VRTX   -8.07%    
• View Complete Report
   



Business Update

Cadrenal Therapeutics Partners with Abbott to Advance Pivotal Study of Tecarfarin in LVAD Patients

Published Tue, Mar 18 2025 4:27 AM UTC

Cadrenal Therapeutics, Inc. (NASDAQ: CVKD), a late-stage biopharmaceutical company focused on the development of specialized cardiovascular therapeutics, has announced a significant advancement in its clinical pipeline. The company has entered into a collaboration agreement with Abbott (NYSE: ABT) to support its pivotal clinical trial, the TECarfarin Anticoagulation and Hemo...
Business Update

Cadrenal Therapeutics Pioneering the Future of Anticoagulant Therapy with Tecarfarin,

Published Sat, Jan 4 2025 6:03 PM UTC

PONTE VEDRA, Fla. Cadrenal Therapeutics, Inc. (Nasdaq: CVKD) has recently delivered a comprehensive year-end update for 2024, illuminating its ambitious vision for the investigational drug tecarfarin. As a pioneering effort in the realm of anticoagulation therapy, tecarfarin aims to set a new standard of care for warfarin-dependent patients utilizing implanted cardiac devi...
Business Update

Cadrenal Therapeutics Charts a Promising Future Advancement of Tecarfarin as a Revolutionary Anticoagulant Therapy fo...

Published Fri, Jan 3 2025 8:00 PM UTC

Cadrenal Therapeutics Provides 2024 Year-End Company Update, Reinforcing Clinical Development Plan for Tecarfarin in LVAD and Other Rare Cardiovascular Indications PONTE VEDRA, Fla. Cadrenal Therapeutics, Inc. (Nasdaq: CVKD) recently concluded its year-end review for 2024, articulating a robust framework aimed at advancing the clinical development of tecarfarin, a novel ...
Business Update

Cadrenal Therapeutics, based in Ponce de Leon, Florida, recently provided an insightful year-end update for...

Published Wed, Jan 1 2025 4:39 PM UTC

Cadrenal Therapeutics Charts a Promising Course for Tecarfarin Development in 2024: A New Dawn for Anticoagulant Therapy in Cardiovascular Care Cadrenal Therapeutics, based in Ponce de Leon, Florida, recently provided an insightful year-end update for 2024, reinforcing its commitment to advancing the clinical development of its investigational drug, tecarfarin. The company h...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) -
Price to Sales (Expected) -
Price to Book 0.83
PEG (TTM) -

Financial Strength Current
Quick Ratio 2.99
Working Capital Ratio 3.73
Leverage Ratio (MRQ) 0.37
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -5.84 $
Revenues (TTM) -
Cash Flow (TTM) -
Cash 1.54 $
Book Value 1.4 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) -
Net Income per Employee (TTM) -2,542,911
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) -

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -
Net Margin (MRQ) -
Net Cash Flow Margin (MRQ) -
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -






Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.